Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
SPECTROBID (bacampicillin hydrochloride) is an oral aminopenicillin antibiotic approved in 1982 for bacterial infections susceptible to ampicillin. It is a prodrug of ampicillin that offers improved oral bioavailability and broader tissue penetration. The drug works by inhibiting bacterial cell wall synthesis through beta-lactam mechanism of action.
As LOE approaches after 40+ years on market, the brand team is likely in maintenance mode with minimal commercial expansion and reduced headcount allocation.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on SPECTROBID offers limited career growth potential due to its LOE status and zero linked job openings; roles are primarily maintenance-oriented with focus on operational efficiency and margin protection. This product is better suited for early-career professionals seeking stable, commodity-focused experience or specialists in end-of-life brand management.
Worked on SPECTROBID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.